ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 984,93
-0,99%
Dow Jones
37 903,29
0,23%
DAX
17 932,17
-1,10%
Brent Oil
83,54
-2,74%
Bitcoin
57 911,98
-4,44%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Immunovant Inc (IMVT)

  7. Immunovant Inc (IMVT) Actualités

IMVT Immunovant Inc

28,52
1,08 (3,94%)
Après les heures de négociation
Dernière mise à jour : 00:04:45
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Immunovant Inc IMVT NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
1,08 3,94% 28,52 00:04:45
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
27,31 27,30 29,26 28,52 27,44
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
12/3/202412:30GLOBEImmunovant Awarded U.S. Patent for IMVT-1402
23/2/202422:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/2/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202414:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
12/2/202413:05EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
12/2/202413:02EDGAR2Form 8-K - Current report
29/1/202422:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19/1/202422:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
16/1/202413:29EDGAR2Form 3 - Initial statement of beneficial ownership of..
12/1/202422:34EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:20EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202422:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
09/1/202414:08EDGAR2Form 8-K - Current report
03/1/202414:00GLOBEImmunovant to Present at the 42nd Annual J.P. Morgan..
20/12/202323:40DJNImmunovant Gets Positive Data From Graves' Disease Treatment..
20/12/202322:37EDGAR2Form 8-K - Current report
20/12/202322:30GLOBEImmunovant Reports Positive Initial Phase 2 Results for..
28/11/202313:43EDGAR2Form 8-K - Current report
28/11/202313:00GLOBEImmunovant Announces Positive IMVT-1402 Initial 600 mg MAD..
24/11/202320:55EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:47EDGAR2Form 4 - Statement of changes in beneficial ownership of..
24/11/202320:45EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/11/202314:00GLOBEImmunovant to Present at Upcoming Investor Conferences
09/11/202314:49EDGAR2Form S-3ASR - Automatic shelf registration statement of..
09/11/202313:13EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
09/11/202313:06EDGAR2Form 8-K - Current report
09/11/202313:00GLOBEImmunovant Reports Financial Results and Provides Corporate..
20/10/202322:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
11/10/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202323:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/10/202323:10EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/10/202322:52GLOBEImmunovant Announces Closing of Upsized Common Stock..
29/9/202322:48EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
28/9/202323:23EDGAR2Form 8-K - Current report
28/9/202312:09EDGAR2Form FWP - Filing under Securities Act Rules 163/433 of free..
28/9/202305:41GLOBEImmunovant Announces Pricing of $450 Million Common Stock..
26/9/202323:28EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
26/9/202323:00GLOBEImmunovant Announces Proposed Offering of $300 Million of..
26/9/202313:45EDGAR2Form 8-K - Current report
26/9/202312:00GLOBEImmunovant Announces Positive Initial IMVT-1402 Phase 1 SAD..
26/9/202305:01GLOBEImmunovant to Host Conference Call and Webcast to Report..
01/9/202322:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202323:03EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202323:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202322:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
23/8/202322:48EDGAR2Form 8-K - Current report
16/8/202322:11EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/8/202313:19EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]

Dernières Valeurs Consultées

NASDAQ
IMVT
Immunovant
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés